FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Emerald Health Sciences Inc.		 2. Issuer Name and Ticker or Trading Symbol

Skye Bioscience, Inc. [ SKYE ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    __X__ 10% Owner
_____ Officer (give title below)    _____ Other (specify below)
(Last)          (First)          (Middle)

OFFICE 8262, THE LANDING, 200-375 WATER ST.		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/10/2022
(Street)

VANCOUVER, A1 V6B 0M9
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 2/22/2023  A  16641486 A$0.017 128028737 D  
Common Stock 2/22/2023  A  41379164 A$0.0386 169407901 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Warrants $0.151 11/10/2022  J/K (1)  9141486    11/10/2023 12/30/2024 Common Stock 9141486 $0 9141486 D  
Warrants $0.017 2/22/2023  D     9141486  11/10/2023 12/30/2024 Common Stock 9141486 $0 0 D  
Warrants with Credit Facility of Oct 5, 2018 $0.0386 2/22/2023  P     2500000  11/1/2018 11/1/2023 Common Stock 2500000 $0 0 D  
Warrants with Credit Facility of Oct 5, 2018 - T2 $0.0386 2/22/2023  D (2)    2500000  2/1/2019 2/1/2024 Common Stock 2500000 $0 0 D  
Warrants with Credit Facility of Oct 5, 2018 - T3 $0.0386 2/22/2023  D (2)    2500000  3/29/2019 3/29/2024 Common Stock 2500000 $0 0 D  
Explanation of Responses:
(1) Warrants were acquired pursuant to a merger between Issuer and Emerald Health Therapeutics, Inc. ("Emerald"), whereby Reporting Person's outstanding warrants to purchase Emerald common stock were exchanged for warrants to purchase Issuer common stock.
(2) Aggregate exercise price for the warrants was paid through a reduction in the debt Issuer owed to Reporting Person under the Multi Draw Credit Facility.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Emerald Health Sciences Inc.
OFFICE 8262
THE LANDING, 200-375 WATER ST.
VANCOUVER, A1 V6B 0M9
X
Signatures
/s/ Stephen Hall, CFO of Emerald Health Sciences Inc.3/15/2023
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Grafico Azioni Skye Bioscience (QB) (USOTC:SKYE)
Storico
Da Mag 2024 a Giu 2024 Clicca qui per i Grafici di Skye Bioscience (QB)
Grafico Azioni Skye Bioscience (QB) (USOTC:SKYE)
Storico
Da Giu 2023 a Giu 2024 Clicca qui per i Grafici di Skye Bioscience (QB)